AMD 

Cataract & Refractive

Cornea

Gene Therapy

Glaucoma

Inflammation & Infection

Paediatrics

Retina

Articles

Media

All Videos

Eyeviews

Insights

Medical World News

Podcasts

Rapid Readouts

Viewpoints

Publications

Digital Edition

Supplements And Featured Publications

Conferences

Conference Listing 

CME/CE

Resources

ZEISS Clinical Cases

Zeiss Cataract Insights

Zeiss Cataract Digitalization

Enhancing the Patient Journey

EYLEA 8mg for nAMD and DME Treatment

Between the Lines

Subscribe

Advertise

About Us

Editorial Info

Editorial Board

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Ophthalmology Times Europe

Facebook

LinkedIn

Spotlight

High-Frequency Deep Sclerotomy

iCare COMPASS Automated Perimeter

Clinical

1rem

Authors

The implantable lenses can offer an advantage over laser surgery

For younger patients with mid-range myopia, consider phakic IOLs

A very-high-frequency ultrasound device provides a range of detailed intraocular measurements that enable highly accurate ICL sizing and placement. 

Very-high-frequency ultrasound improves ICL sizing precision

The European Commission provided a positive opinion from the European Medicines Agency (EMA) Committee for Advanced Therapies, providing an Advanced Therapy Medicinal Product (ATMP) classification to OCU400 (Ocugen, Inc.). OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication.

ATMP classification is given to medicines that allow for innovative opportunities for the treatment of disease, thus accelerating the regulatory review timeline of the new gene therapy. The classification will also allow for further collaboration between Ocugen and the EMA, with the EMA in place for scientific advice and protocol assistance as the company pushes for Marketing Authorisation Application (MAA) filing in 2026.

“Receiving ATMP classification is another significant milestone toward bringing OCU400 to the market in Europe,” said Shankar Musunuri, chairman, CEO and co-founder of Ocugen. “This designation makes it possible to stay on track with our clinical and commercial strategy and potentially provide this novel modifier gene therapy candidate to all RP patients in the United States and Europe by 2027.”

Besides the EMA, the FDA has also acknowledged that the Phase 3 trial of OCU400 can suffice for Biologics License Application (BLA) and MAA submissions. Ocugen, Inc. plans to file simultaneously in the US and Europe after completion of the trial.

Currently, the Phase 3 OCU400 trial is undergoing enrollment, and the study has a sample size of 150 participants. Patients 8 years old and older with early through late-stage advancement of RP are being recruited to take part in the study.

“We are encouraged by the EMA’s recognition of OCU400 as the Phase 3 liMeliGhT clinical trial advances,” Huma Qamar, chief medical officer at Ocugen, said. “I look forward to working collaboratively with the EMA to address the unmet medical need that remains for nearly 98% of the RP patient population.”

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advance Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa. News release. Ocugen. Published February 3, 2025. Accessed February 3, 2025. https://www.globenewswire.com/news-release/2025/02/03/3019337/0/en/Ocugen-Announces-Positive-Opinion-of-European-Medicines-Agency-s-Committee-for-Advanced-Therapies-for-Advanced-Therapy-Medicinal-Product-Classification-for-Modifier-Gene-Therapy-Ca.html

OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication

Ocugen, Inc. receives European Medicines Agency ATMP designation for new gene therapy OCU400

On 13 January, Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., announced it would partner with Klinge Biopharma GmbH and Formycon AG in commercialising FYB203, Formycon’s biosimilar candidate to aflibercept (Eylea, Regeneron Pharmaceuticals Inc.) in designated regions of Europe.

 On 5 February, Formycon announced that Klinge Biopharma had also concluded an exclusive license agreement with Lotus Pharmaceutical.

 This new agreement will enable commercialisation of the product throughout the Asia-Pacific region. Pending regulatory approval, the product will be marketed under the brand name AHZANTIVE.

Under these agreements, Teva will lead the commercialisation effort in designated regions of Europe, excluding Italy, and in Israel. Lotus Pharmaceutical will lead commercialisation in Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam, as well as within the Special Administrative Region Hong Kong.

Previously, Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis). Nicola Mikulcik, hief business officer of Formycon, commented on the expansion of the partnership. “With Teva, we are gaining a strong and proven partner for FYB203 in the major parts of Europe and Israel. Teva is already marketing our FYB201 ranibizumab biosimilar (Ranivisio/Ongavia) in Europe and can synergistically leverage an existing commercial infrastructure and well-established distribution channels in the ophthalmology field,” she said in the press release.

 “We are pleased to build on this trusted and successful collaboration. Particularly noteworthy is Formycon’s first-time responsibility for managing the entire commercial supply chain of the finished product.”

Like its reference product, the biosimilar FYB203 is an anti-vascular endothelial growth factor (VEGF) agent used to treat retinal disease. Chief among those indications is neovascular age-related macular degeneration (AMD), also known as wet AMD.

In November 2024, the European Medicines Agency's Committee for Medicinal Products of Human Use issued a positive recommendation for marketing authorisation of FYB203, under the brand names AHZANTIVE/Baiama. The European Commission is expected to announce a response to the authorisation application in late January 2025.

In June 2024, the US Food and Drug Administration (FDA) approved the biosimilar FYB203, also known as aflibercept-mrbb. In a press release at that time, the company stated3 that FDA approval was rooted in the company's “comprehensive data package” that included “analytical, pre-clinical, clinical and manufacturing data.” The data showed that FYB203 demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference product in patients with neovascular AMD.

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel. News release. Teva Pharmaceutical Industries Ltd. Published January 13, 2025. Accessed January 13, 2025. https://www.globenewswire.com/news-release/2025/01/13/3008103/0/en/Teva-Announces-Collaboration-to-Commercialize-Formycon-s-Biosimilar-Candidate-to-Eylea-aflibercept-in-major-parts-of-Europe-and-in-Israel.html

Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region. News release. Formycon AG. Published February 5, 2025. Accessed February 5, 2025.

Harp M. FDA approves Formycon’s biosimilar to Eylea, aflibercept-mrbb (Ahzantive). Ophthalmology Times. Published July 2, 2024. Accessed January 13, 2025. https://www.ophthalmologytimes.com/view/fda-approves-formycon-s-biosimilar-to-eylea-aflibercept-mrbb-ahzantive-

The commercialisation agreements for the biosimilar to aflibercept (Eylea) cover Israel, major parts of Europe and the Asia-Pacific Region

Teva partners with Klinge Biopharma, Lotus Pharmaceutical for commercialisation of Formycon’s FYB203 (biosimilar aflibercept)

Over the last 15 years, biosimilars have become a major feature of the health care landscape. Physicians in many disciplines, particularly oncology and immunology, have embraced biosimilars. However, access to educational resources on these powerful biologics can be inconsistent, and in turn, some ophthalmologists who could benefit from the adoption of biosimilars are left in the dark.

The real-world application of biosimilars was the focus of discussion for Martin Zinkernagel, MD, PhD, chair of the Department of Ophthalmology at the University Hospital of Bern, Switzerland, and Paolo Lanzetta, MD, professor of ophthalmology and chairman of the Department of Medicine-Ophthalmology at the University of Udine in Italy. In their discussion, the experts addressed several common questions, framed around the phase 3 clinical trial for biosimilar SB11 (BYOOVIZ) from Biogen. SB11 is approved in Europe and the United Kingdom. Like the reference product ranibizumab (Lucentis), SB11 is approved for the treatment of retinal disease including neovascular age-related macular degeneration (nAMD).

Addressing physicians’ levels of familiarity with biosimilars, Dr Lanzetta attributed much of the variation to regulatory discrepancies. “The uptake of biosimilars varies throughout Europe by country and by product,” he said. “Obviously, variation in the uptake of biosimilars [is] influenced by government involvement, reimbursement issues and tender procurement policies.” Recent survey data have revealed gaps in awareness across Europe and in the United States on the efficacy and safety of biosimilars for retinal diseases, Dr Lanzetta said, especially in terms of “real-world data.”

In a clinical application, Dr Lanzetta said, biosimilars may exhibit minor differences from the reference products, but they aren’t considered to have significant impact on the efficacy or safety profile. Typically, the biosimilar and reference medicine must have the same posology and route of administration, with few exceptions, he added.

Dr Lanzetta also said that in the last 10 years, the European Medicines Agency (EMA) has approved the highest number of biosimilars worldwide.

 “And this means, to us physicians, having both the possibility to have experience on their use in terms of safety and evaluating the efficacy after that,” he explained.

One common misconception about biosimilars is that these therapeutics are interchangeable with the idea of generic medicines. But there is a key indicator that biosimilars are unique: the cost. “While generic medicines are marketed at a significantly lower price than name brand ones, why do we not see the same level of cost savings with biosimilars?” Dr Zinkernagel asked.

Dr Lanzetta explained that biosimilars are developed via a rigorous, complex and highly regulated manufacturing process. “Generics are simple chemical medicines or agents, which is not the case for biosimilars and biologics,” he said. “Unlike generics, biologics, and therefore biosimilars as well, are very complex; they’re very difficult to copy. And the development processes are patented and proprietary to the originators.” The proprietary nature of biologic development, he added, is why biosimilars may have differences from their originators.

Prof Zinkernagel and Dr Lanzetta used data from the SB11 phase 3 trial to expand upon the capabilities of biosimilars. Prof Zinkernagel detailed the study: over 700 patients were included in the randomised, double-masked, parallel-group multicentre trial. Over 52 weeks, investigators evaluated the efficacy and the safety profile of this biosimilar SB11 in comparison with monthly ranibizumab for the treatment of nAMD.

“Patients with neovascular AMD were included, [with a] visual acuity range between 20/40 and 20/200,” Prof Zinkernagel said. “[Patients] were randomised in a 1:1 ratio to either have the originator or the biosimilar every 4 weeks from baseline up to week 48.”

Primary end-points were change from baseline in best corrected visual acuity at week 8 and change from baseline in central subfield thickness at week 4. The pre-specified secondary efficacy end-points included longer-term assessments of change from baseline in visual acuity, and the proportion of participants who lost fewer than 15 letters or who gained 15 or more letters in visual acuity from baseline at weeks 24 and 52.

“Other secondary end-points included, of course, change from baseline in central subfield thickness and central retinal lesion thickness at week 24, as well as change from baseline in choroidal neovascularisation [CNV] size and proportion of participants with active CNV leakage seen via OCT [optical coherence tomography] at week 24,” Prof Zinkernagel continued. Describing the results, he said, “When you look at the visual acuity improvements, it’s really equivalent. You have equivalence between the originator and the biosimilar, and the same holds true for a decrease in central retinal thickness. So the curves are basically the same, and also the secondary end-points.”

Prof Zinkernagel also spoke about the immunogenicity outcomes of the SB11 trial, as immunogenicity reactions have been a common problem in past assessments of anti–vascular endothelial growth factor (VEGF) agents. Along with detrimental effects to visual acuity, immunogenicity reactions can also lead to vasculitis and vitritis.

“Now, in this trial, the overall cumulative incidence of anti-drug antibodies, antibodies reacting against this specific drug up to week 52, was very low,” Prof Zinkernagel said. “For the SB11 biosimilar, it was 4.2%, and for the originator it was 5.5%. So very, very similar.”

He also noted that most antibodies were non-neutralising, which generally indicates a weak antibody response. “Furthermore, no statistical or clinically relevant differences in the incidence of anti-drug antibodies and neutralising antibodies were observed between treatment groups at any of the time points,” Prof Zinkernagel explained.

Dr Lanzetta highlighted the unique potentialities for anti-VEGF therapies as an area where physicians can consider treating patients with a biosimilar. “You can either switch a patient from the originator, obviously, or you can also consider treating with a biosimilar treatment-naive patients who may benefit…from being treated with that reference agent or originator agent,” he said. When to deploy a biosimilar will depend on many factors, including the locality where a patient is being treated. “Europe has different countries, different health care systems,” Dr Lanzetta said. “You may consider treating with the biosimilar patients who may not be strictly adherent to the cost of therapy and the frequency of treatment because of some cost issues.”

Just as education on biosimilars is vital to practitioners, awareness and education resources for patients are vital, too. “We spend a lot of time with our patients in letting them know that biologics did undergo a very rigorous approval process through studies, efficacy and safety studies,” Dr Lanzetta emphasised. This education is vital to getting patients on board with biosimilars, and it sparks enthusiasm about the potential benefits. “Once they do understand that, I think they will be very prone to receive a biosimilar; [it’s] in their interest and in the interest of the community, the whole community of patients, and in the interest of the health care system,” Dr Lanzetta said.

1. Biosimilars in the EU: information guide for healthcare professionals. European Medicines Agency. Updated December 2, 2019. Accessed October 3, 2023. 

https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pd

Editor’s note: A prior version of this article contained a misspelling of the product name BYOOVIZ. It has been corrected. We regret the error.

How biosimilars expand treatment options for patients with retinal disease

Novelty Nobility, a Korean antibody drug discovery company, recently announced it has been selected to join JLABS Korea.

 JLABS, part of Johnson & Johnson’s global incubator network, supports startups in their efforts by offering access to expertise, development resources, strategic partnerships, as well as investor networks in the healthcare space.

Specialising in advanced modality antibody drugs, as part of JLABS Korea, Novelty Nobility will focus on developing two antibody candidates, according to a press release:

: a bispecific antibody candidate to target c-Kit and vascular endothelial growth factor (VEGF) for vascular retinal diseases

: an antibody-drug conjugate (ACD) candidate to target Pan-RAS-mutated solid tumours.

The JLABS programme is available in 11 locations across the globe, including China, the United Kingdom, Canada, and throughout the United States. There are also virtual residencies in Korea, Singapore and a regional residency for Europe, the Middle East and Africa.

Park Sang-gyu, chief executive officer of Novelty Nobility, said in a press release the company will “leverage” JLABS Korea to “enhance the competitiveness of [the company’s] early-stage follow-up on pipeline in the global market.”

Novelty Nobility’s pipeline targets therapeutic areas such as immune disorders, cancer and ophthalmic diseases that can utilise antibody treatments.

Two separate institutions awarded Novelty Nobility A grades in July 2024 in the technical evaluation for a special listing on the Korean Securities Dealers Automated Quotations (KOSDAQ). The company has also recently filed a preliminary listing application.

“We are committed to advancing our pipeline and achieving meaningful business outcomes through collaborative research with global pharmaceutical companies,” Sang-gyu said in a press release.

1. Sook H. Novelty Nobility joins Johnson & Johnson’s JLABS Korea to advance antibody drug pipeline. KBR. Published April 8, 2025. Accessed April 9, 2025. https://www.koreabiomed.com/news/articleView.html?idxno=27206

The company's therapeutic candidates include a bispecific antibody to target vascular retinal diseases

Antibody drug discovery company Novelty Nobility joins Johnson & Johnson JLABS Korea

Though its name may seem intimidating, the Congress on Controversies in Ophthalmology (COPHy) welcomes the conflict-averse clinician. Held this year in Seville, Spain, on 4 and 5 April, the 16th annual edition of COPHy will pit some of the greatest ophthalmic leaders against each other on a global stage. 

The head-to-head “combat” may seem a little startling to the uninitiated—scientific congresses do not usually embrace the often contradictory elements of research. But co-chairs Baruch Kuppermann, MD, PhD, and Anat Loewenstein, MD, told 

 that the COPHy meeting is built around the circumstances real physicians face every day.

“What is very unique about COPHy is that, in your daily management of patients, you deal with topics that are controversial,” said Prof Loewenstein, who is head of the Department of Ophthalmology at the Tel Aviv Medical Center in Tel Aviv, Israel. “So, the meeting is structured in a way that attracts clinicians who are open to change, and who want to learn more about clinically significant topics that are widely interesting.”

Prof Kuppermann, who is the director of the Gavin Herbert Eye Institute at the University of California Irvine, echoed that sentiment, saying that COPHy serves to highlight the abundance of clinical and technological choices available to modern-day clinicians. “We want it to be as collegial as possible. We don’t do a pre- and post-debate vote,” he noted. “We are trained to be thoughtful, and to keep an open mind, but also a critical mind.”

The session format at COPHy grants each participant in a debate 10 minutes to establish their “yes” or “no” position. The questions largely focus on medical and surgical retina topics, though the meeting is expanding its coverage beyond the retina speciality. The debate speakers may address long-standing practices (“Is steroid therapy for diabetic macular oedema still relevant in the era of new-generation anti-VEGF agents?”) or questions of the near and distant future (“Can artificial intelligence [AI] predict the success of retinal detachment surgery?”).

A factor which makes COPHy debates unique is that there is no rebuttal period, Prof Kuppermann said. In most academic or scientific debates, the participants are granted a brief rebuttal to defend their initial opinions and challenge the theories posited by their competitors. Instead, at COPHy, the debate is followed by a 10-minute discussion, moderated by a neutral expert in the topic at hand.

“The discussion is the most important part of the meeting,” said Prof Loewenstein. “It’s really a resource for education. The moderator is usually someone with a lot of experience, who can summarise both sides and reach some sort of a conclusion.” 

Keeping the focus on a “yes” or “no” question, restricting the argument to two opposing viewpoints, is also key to the success of a COPHy debate, she said. It illuminates the clinical questions at hand, helping practitioners glean the most valuable insights for their own practices.

“We structure the debate so there is a clear, legitimate pathway for arguing the ‘no’ position,” Prof Kuppermann added. “We want the debate to be thoughtful and let there be nuance. We demonstrate that there is more than one way to look at a clinical situation, but keep the debate focused, so we aren’t addressing 

Because the debates are developed with intention, Prof Kuppermann said, it also allows the co-chairs and faculty to refine the role industry plays in COPHy programming. Some debates are sponsored by a “topic-agnostic,” objective industry partner, and there are also industry symposia as well as a sponsored speaker’s corner. This year, companies also have the opportunity to sponsor specific debate topics—alone or alongside other players in the ophthalmic industry—without any authority over the agenda.

This new multi-sponsor model is especially effective in areas where there is a lot of recent research or rapid growth, said Prof Loewenstein. “When the topic is sponsored by a few different companies, it gives additional validity, credibility and objectivity [to the discussion],” Prof Loewenstein said. “You see so many companies now which are working with device-based drug-delivery implants, or many companies exploring genetic treatment. The combined sponsorships give us a chance to explore those topics and also help us gauge interest in them.”

Historically, the scientific programme at COPHy has focused on retina care. Prior forays into the anterior segment were temporary. Recent additions to the programming—uveitis, glaucoma and neuro-ophthalmology—reflect an expanding interest in the meeting and a shift in clinicians’ interests. Prof Loewenstein and Prof Kuppermann both expressed gratitude to Bahram Bodaghi, MD, PhD, FEBO, and Zohar Habot-Wilner, MD, who organise the uveitis section; Francesca Cordeiro, MBBS, PhD, FRCOphth, who organises the
glaucoma section; and Andrew G. Lee, MD, who organises the neuro-ophthalmology section.

“Neuro-ophthalmology and uveitis are things that really intrigue people, intellectually,” Prof Kuppermann said. “Those are, in many ways, our most complex sub-specialities within ophthalmology, and we all want to learn more from the leaders in those fields.”

“Francesca [Cordeiro] approached us about adding glaucoma as a topic, and we had it in 2024,” said Prof Kuppermann. He described glaucoma as a topic with “hybrid” appeal to attendees and sponsors, and Prof Loewenstein said it is a topic that has received positive feedback from scientists attending and participating in the programme. “Glaucoma has vocal proponents, and we would love to have this be a regular part of our meeting,” Prof Kuppermann said. “We’re going to see how much sponsorship we can attract to make it an ongoing part [of COPHy].”

Though COPHy is broadening its coverage, rigorous standards still apply to the debate topics and the questions explored on-stage, Prof Loewenstein said. “When you look at the programme, you can see that it is clinically oriented and focused on how to treat specific patients,” she said. “We expanded the programme because we want it to be valuable to the general ophthalmologists who come from all over the world, and particularly for the clinicians in our host country.”

A regional advisory board helps Prof Loewenstein and Prof Kuppermann make the most of each year’s COPHy sojourn. This year, Patricia Udaondo, MD, PhD, FEBO, is the local chair for the meeting. Dr Udaondo is the co-founding director and head of the retina division of Aiken Ophthalmological Clinic in Valencia, and part of the medical-surgical retina division at University and Polytechnic Hospital La Fe, Valencia, both in Spain.

“Dr Udaondo is a leader in this field and within Spain, and she contributes so much to the programme and to the meeting,” Prof Loewenstein said. “Our Spanish colleagues are leaders in many areas of ophthalmology, especially within retina, and Spain has some of the best retinal surgeons in the world. We look forward to learning from them in the surgical retina sessions.”

Prof Kuppermann noted that the regional advisory board not only helps organise the logistics of the meeting, but also imbues each annual COPHy meeting with unique takeaways that the global audience may otherwise not encounter. “Dr Udaondo has helped guide us by letting us know what’s of interest in Spain. There is a surprising amount of regional variation within clinical practices, and we always try to design a few debates that are of particular interest to the host country,” he said.

Debates are the core of COPHy, but the first day of the meeting closes out with a panel, a format which might be more familiar to attendees of other conferences. This anomaly is no mistake. The panel features a roster of global leaders in retina care discussing a topic which Prof Kuppermann and Prof Loewenstein both characterised as one of the “most controversial” of different years.

That panel will focus on expert opinions on the use of new treatment regimens with extended injection intervals. Prof Kuppermann said the discussion is decades in the making.

“The anti-VEGF era started 20 years ago. It was the 2005 American Society of Retina Specialists (ASRS) meeting in Montréal, Quebec, Canada,” Prof Kuppermann said. At that year’s ASRS meeting, said Kuppermann, the ophthalmic community was introduced to the research findings for intravitreal use of bevacizumab and ranibizumab for treatment of age-related macular degeneration (AMD). “At that podium, in July 2005, was the ‘hallelujah’ moment for AMD,” he said.

“Anti-VEGF therapy for retinal disease, and exactly how we should use it, has always been a controversial issue,” Prof Loewenstein agreed. “At first, the argument was ‘Use this one drug over the other drug.’ Then it became a question of regimens, and slow-release devices, and now higher doses and whether we need to implement other mechanisms.”

Over the 16 years of the COPHy meeting, Prof Loewenstein noted, the use of anti-VEGF agents is a thread that has been picked up again and again. The volume of research is what necessitates a panel discussion on new treatment regimens, she and Prof Kuppermann both said. “We have so much data already on this topic, and there is more coming out, constantly,” Prof Loewenstein said. “You have so much data, so many therapies available now, and so many therapies coming out. It’s in the best interests of the patients to keep the discussion here more comprehensive.”

Prof Kuppermann said he was surprised by the continuing relevance of the extended injection interval discussion. “I don’t think that, in 2005, most of us would have believed that [anti-VEGF] agents would be the mainstay therapy, and still be so popular,” he said. “Here we are, 20 years later, still giving regular injections, and the debates still continue.” 

There are still many mysteries related to AMD, he said, and the best measures for individual patients’ treatment goals. “There are emerging debates, too, about geographic atrophy, about genetic therapies,” he said. “This helps you realise that it’s often not a matter of what is controversial, but more a question of how we can best meet patients’ unmet needs.”

Prof Loewenstein concluded by thanking all the clinicians who are willing to share their perspectives, in debates and on the panel, even when it means going against the grain. It is all in service to the patients, she added, and if each attendee takes just one lesson or clinical pearl back to their practice, she will be satisfied.

“We want people to leave this meeting and say ‘You know, I heard this debate, and I heard these positions, and ultimately, I was convinced,” Prof Loewenstein said. “When we open up these discussions, we can give so much knowledge, and so many tools, to clinicians.”

This year, the COPHy meeting moves beyond retina, addressing uveitis, neuro-ophthalmology and glaucoma in Seville, Spain

Up for debate: Clinicians take on hot topics at the Congress on Controversies in Ophthalmology

On Tuesday, 11 March, Her Royal Highness the Duchess of Edinburgh, delivered a keynote address to United Nations ambassadors and agency staff advocating for gender equity in eye health. Her Royal Highness is a global ambassador for the International Agency for the Prevention of Blindness (IAPB), and as part of this role, she delivered the keynote at a UN Friends of Vision group meeting, presented in partnership with The Fred Hollows Foundation. 

The event was timed to coincide with the UN Commission on the Status of Women, shortly after International Women’s Day and during Women’s History Month in the US.

Her Royal Highness called on policymakers, health care leaders and UN ambassadors to take action and support eye care access, particularly for women and girls. In her speech, she emphasised the far-reaching impact of ocular health initiatives.

“Eye health is not simply one health concern, but can be a proactive driver of development,” the Duchess of Edinburgh said. “The ability to see is directly linked to productivity and participation, impacting families, communities and economies.”

Her Royal Highness cited programmes in Vanuatu and Vietnam, aimed at trachoma elimination, as examples of successful eye health initiatives. Vanuatu and Vietnam recently achieved trachoma-free status, per the World Health Organisation. The data-driven eye health programmes which made this possible have also illuminated the gender discrepancies that are endemic to many countries, she pointed out. 

"We now have confirmation that women are disproportionately affected by trachoma through gender issues including high contact with children, repeated infections, low uptake or access to services for women,” Her Royal Highness said.

Additionally, the Duchess of Edinburgh spoke about the UN Resolution Vision for Everyone, and the upcoming Global Summit for Eye Health organised by the IAPB. "We now find ourselves at a moment in time when universal eye health could be accessible to everyone, globally," she said. "I thank you for your attention on this vital cause, which unlike many other complex challenges being discussed this week [during the UN Commission on the Status of Women], is simple, impactful, cost-effective and scalable."

Jennifer Gersbeck, executive director of influence and scaling impact at the Fred Hollows Foundation, shared additional statistics to emphasise the global import of ocular health measures.

“Women and girls make up 55% of the world’s blind and vision impaired, yet when they can’t access the eye care that they need, it entrenches them further in poverty. Without urgent action, millions of women and girls will continue to be left behind,” she stated. “The Commission on the Status of Women is a critical opportunity to advocate for concrete policies and investment to ensure all women and girls have access to quality eye care, unlocking their full potential.”

Her Royal Highness also said that addressing eye health furthers the UN objective to achieve its Sustainable Development Goal (SDG) agenda. “By tackling the issue of blinding trachoma, as well as other eye health issues within vulnerable communities, we are also positively impacting other neglected tropical diseases,” she said. “We are also aligning our priorities with broader health and development targets, but prioritising eye health working towards achieving the SDGs by 2030."

Duchess of Edinburgh Highlights Critical Link Between Eye Health & Gender Equity at UN Commission on the Status of Women. Press release. International Agency for the Prevention of Blindness. Published March 11, 2025. Accessed March 12, 2025. 

https://www.iapb.org/news/duchess-of-edinburgh-highlights-critical-link-between-eye-health-gender-equity-at-un-commission-on-the-status-of-women/

Speech by HRH The Duchess of Edinburgh, Global Ambassador for the International Agency for the Prevention of Blindness. Published March 11, 2025. Accessed March 12, 2025.

The UN Friends of Vision group meeting coincided with International Women's Day and the UN Commission on the Status of Women

Dr Brett Mueller

Articles

Latest Updated Articles